A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Yu C, Zhang F, Ding Y, Li Y, Zhao Y, Gu J, Guo S, Pan W, Jin H, Sun Q, Kang X, Yang Q, Jiang X, Song Z, Lu Q, Pang X, Kuang Y, Deng D, Li Y, Zhang C, Tao J, Xie L, Wang Y, Wang J, Wang G.
Yu C, et al.
Int Immunopharmacol. 2022 Nov;112:109248. doi: 10.1016/j.intimp.2022.109248. Epub 2022 Sep 18.
Int Immunopharmacol. 2022.
PMID: 36126411
Clinical Trial.